Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
38°
Clear
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Tourmaline Bio, Inc. - Common Stock
(NQ:
TRML
)
15.27
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 22, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Tourmaline Bio, Inc. - Common Stock
< Previous
1
2
Next >
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
April 02, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
Why FactSet Research Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
March 21, 2024
Shares of FactSet Research Systems Inc. (NYSE: FDS) fell sharply during Thursday’s session after the company reported worse-than-expected second-quarter revenue and issued FY24 guidance.
Via
Benzinga
TRML Stock Earnings: Tourmaline Bio Reported Results for Q4 2023
March 19, 2024
Tourmaline Bio just reported results for the fourth quarter of 2023.
Via
InvestorPlace
12 Health Care Stocks Moving In Thursday's Intraday Session
March 21, 2024
Via
Benzinga
Dow Jumps 200 Points; US Weekly Jobless Claims Fall
March 21, 2024
U.S. stocks traded higher this morning, with the Dow Jones index gaining around 200 points on Thursday. Following the market opening Thursday, the Dow traded up 0.52% to 39,718.37 while the NASDAQ rose...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results
March 21, 2024
Investors saw Chugai's experimental drug as a potential rival to Argenx's approved medicine, Vyvgart.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Thursday's Pre-Market Session
March 21, 2024
Via
Benzinga
Five Below Posts Q4 Results, Joins LexinFintech And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
March 21, 2024
U.S. stock futures were higher this morning, with the Dow futures gaining by around 100 points on Thursday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
March 19, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
January 29, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio Announces Pricing of Public Offering of Common Stock
January 25, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
January 24, 2024
Via
Benzinga
Tourmaline Bio Announces Proposed Public Offering of Common Stock
January 24, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD)
January 08, 2024
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
TDCX Receives Preliminary Non-binding Proposal Letter, Joins Pure Storage, Dyne Therapeutics And Other Big Stocks Moving Higher On Wednesday
January 03, 2024
U.S. stocks traded lower, with the Nasdaq Composite falling around 150 points on Wednesday. Shares of TDCX Inc. (NYSE: TDCX) rose sharply during Wednesday’s session after it disclosed receiving a...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals
December 29, 2023
Bristol Myers announced two acquisitions in a week. The pharma giant is boosting its neuroscience pipeline with Karuna and its oncology pipeline with RayzeBio.
Via
MarketBeat
Karuna Therapeutics Jumps Following Takeover By Bristol Myers, Joins Rocket Lab USA, Altair Engineering And Other Big Stocks Moving Higher On Friday
December 22, 2023
U.S. stocks traded higher, with the Dow Jones index gaining around 50 points on Friday. Shares of Karuna Therapeutics, Inc. (NASDAQ: KRTX) rose sharply during Friday’s session following acquisition...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
December 22, 2023
Shares of AAR Corp. (NYSE: AIR) fell during Friday’s session after the company reported mixed second-quarter financial results.
Via
Benzinga
Tourmaline Bio added to the NASDAQ Biotechnology Index
December 15, 2023
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board
December 14, 2023
From
Tourmaline Bio, Inc.
Via
GlobeNewswire
Arista Networks, JinkoSolar, Repligen, Shutterstock And Other Big Stocks Moving Higher On Tuesday
October 31, 2023
U.S. stocks traded lower, with the Dow Jones falling more than 50 points on Tuesday. Here are some major stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 31, 2023
Via
Benzinga
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.